SIRPA siRNA (Human)
Référence MBS827854-15nmol
Conditionnement : 15nmol
Marque : MyBiosource
SIRPA siRNA – Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1 (Human)
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS827854MBS827854 is an siRNA targeting SIRPA. Also known as SIRPA siRNA (Human). Reactive in Human. Host: Synthetic. siRNA to inhibit SIRPA expression using RNA interference More details
Product Overview
Online Datasheet in PDFProduct Name
SIRPA, siRNA
Full Product Name
SIRPA siRNA (Human)
Product Gene Name
SIRPA sirna
Product Synonym Names
BIT; MFR; MYD1; PTPNS1; SHPS1; SIRP; Tyrosine-protein phosphatase non-receptor type substrate 1; SHP substrate 1; SHPS-1; Brain Ig-like molecule with tyrosine-based activation motifs; Bit; CD172 antigen-like family member A; Inhibitory receptor SHPS-1; Macrophage fusion receptor; MyD-1 antigen; Signal-regulatory protein alpha-1; Sirp-alpha-1; Signal-regulatory protein alpha-2; Sirp-alpha-2; Signal-regulatory protein alpha-3; Sirp-alpha-3; p84; CD antigen CD172a
Host
Synthetic
Species Reactivity
Human
Form/Format
Lyophilized powder
Purity/Purification
> 97%
Specificity
SIRPA siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight
54,852 Da
OMIM
602461
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SIRPA gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for SIRPA sirna
RNA Interference (RNAi)
Other Notes
Small volumes of SIRPA sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for SIRPA. It may not necessarily be applicable to this product.
NCBI Official Full Name
tyrosine-protein phosphatase non-receptor type substrate 1
NCBI Official Synonym Full Names
signal-regulatory protein alpha
NCBI Official Symbol
SIRPA
NCBI Official Synonym Symbols
BIT; MFR; P84; SIRP; MYD-1; SHPS1; CD172A; PTPNS1
UniProt Protein Name
Tyrosine-protein phosphatase non-receptor type substrate 1
UniProt Synonym Protein Names
Brain Ig-like molecule with tyrosine-based activation motifs; Bit; CD172 antigen-like family member A; Inhibitory receptor SHPS-1; Macrophage fusion receptor; MyD-1 antigen; Signal-regulatory protein alpha-1; Sirp-alpha-1; Signal-regulatory protein alpha-2; Sirp-alpha-2; Signal-regulatory protein alpha-3; Sirp-alpha-3; p84; CD_antigen: CD172a
Protein Family
Tyrosine-protein phosphatase non-receptor
UniProt Gene Name
SIRPA
UniProt Synonym Gene Names
BIT; MFR; MYD1; PTPNS1; SHPS1; SIRP; SHP substrate 1; SHPS-1; Bit; Sirp-alpha-1; Sirp-alpha-2; Sirp-alpha-3
UniProt Entry Name
SHPS1_HUMAN
NCBI Protein Information
tyrosine-protein phosphatase non-receptor type substrate 1
NCBI Summary for SIRPA
The protein encoded by this gene is a member of the signal-regulatory-protein (SIRP) family, and also belongs to the immunoglobulin superfamily. SIRP family members are receptor-type transmembrane glycoproteins known to be involved in the negative regulation of receptor tyrosine kinase-coupled signaling processes. This protein can be phosphorylated by tyrosine kinases. The phospho-tyrosine residues of this PTP have been shown to recruit SH2 domain containing tyrosine phosphatases (PTP), and serve as substrates of PTPs. This protein was found to participate in signal transduction mediated by various growth factor receptors. CD47 has been demonstrated to be a ligand for this receptor protein. This gene and its product share very high similarity with several other members of the SIRP family. These related genes are located in close proximity to each other on chromosome 20p13. Multiple alternatively spliced transcript variants have been determined for this gene. [provided by RefSeq, Jul 2008]
Show more UniProt Comments for SIRPA
SHPS1: Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. Supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. May play a key role in intracellular signaling during synaptogenesis and in synaptic function. Involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin. Mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Binds PTPN11 when tyrosine-phosphorylated, except in macrophages, where it primarily binds PTPN6. Binds GRB2 in vitro. Binds FGR. Binds JAK2 irrespective of its phosphorylation status and forms a stable complex. Binds SCAP1 and/or SCAP2. The resulting complex recruits FYB. Binds PTK2B. Ubiquitous. Highly expressed in brain. Detected on myeloid cells, but not T-cells. Detected at lower levels in heart, placenta, lung, testis, ovary, colon, liver, small intestine, prostate, spleen, kidney, skeletal muscle and pancreas. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Motility/polarity/chemotaxis; Cell adhesion; Cell surface; Receptor, misc.; Membrane protein, integral
Chromosomal Location of Human Ortholog: 20p13
Cellular Component: membrane; integral to membrane; plasma membrane
Molecular Function: SH3 domain binding
Biological Process: cell adhesion; blood coagulation; leukocyte migration
Show more Protein type: Motility/polarity/chemotaxis; Cell adhesion; Cell surface; Receptor, misc.; Membrane protein, integral
Chromosomal Location of Human Ortholog: 20p13
Cellular Component: membrane; integral to membrane; plasma membrane
Molecular Function: SH3 domain binding
Biological Process: cell adhesion; blood coagulation; leukocyte migration
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with SIRPA sirna
| Reference Product | PubMed Publications |
|---|---|
| CD47 sirna | >77 publications with SIRPA and CD47 |
| PTPN11 sirna | >11 publications with SIRPA and PTPN11 |
| PTPN6 sirna | >7 publications with SIRPA and PTPN6 |
| GRB2 sirna | >5 publications with SIRPA and GRB2 |
Pathways associated with SIRPA sirna
| Products by Pathway | Pathway Diagram |
|---|---|
| BDNF Signaling Pathway antibodies | BDNF Signaling Pathway Diagram |
| Cardiac Progenitor Differentiation Pathway antibodies | Cardiac Progenitor Differentiation Pathway Diagram |
| Cell Surface Interactions At The Vascular Wall Pathway antibodies | Cell Surface Interactions At The Vascular Wall Pathway Diagram |
| Cell-Cell Communication Pathway antibodies | Cell-Cell Communication Pathway Diagram |
| Hemostasis Pathway antibodies | Hemostasis Pathway Diagram |
| IL-1 Signaling Pathway antibodies | IL-1 Signaling Pathway Diagram |
| Osteoclast Differentiation Pathway antibodies | Osteoclast Differentiation Pathway Diagram |
| Osteoclast Differentiation Pathway antibodies | Osteoclast Differentiation Pathway Diagram |
| Prolactin Signaling Pathway antibodies | Prolactin Signaling Pathway Diagram |
| Signal Regulatory Protein (SIRP) Family Interactions Pathway antibodies | Signal Regulatory Protein (SIRP) Family Interactions Pathway Diagram |
Diseases associated with SIRPA sirna
| Disease Name | Pubmed Publications |
|---|---|
| Inflammation Antibodies | >25 publications with SIRPA and Inflammation |
| Diabetes Mellitus Antibodies | >16 publications with SIRPA and Diabetes Mellitus |
| Cardiovascular Diseases Antibodies | >16 publications with SIRPA and Cardiovascular Diseases |
| Death Antibodies | >12 publications with SIRPA and Death |
| Disease Models, Animal Antibodies | >10 publications with SIRPA and Disease Models, Animal |
| Breast Neoplasms Antibodies | >9 publications with SIRPA and Breast Neoplasms |
| Necrosis Antibodies | >8 publications with SIRPA and Necrosis |
| Lung Diseases Antibodies | >7 publications with SIRPA and Lung Diseases |
| Kidney Diseases Antibodies | >5 publications with SIRPA and Kidney Diseases |
| Infertility, Male Antibodies | >4 publications with SIRPA and Infertility, Male |
Organs/Tissues associated with SIRPA sirna
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Blood Antibodies | >86 publications with SIRPA and Blood |
| Vascular Antibodies | >23 publications with SIRPA and Vascular |
| Bone Antibodies | >20 publications with SIRPA and Bone |
| Muscle Antibodies | >19 publications with SIRPA and Muscle |
| Prostate Antibodies | >13 publications with SIRPA and Prostate |
| Heart Antibodies | >10 publications with SIRPA and Heart |
| Eye Antibodies | >10 publications with SIRPA and Eye |
| Lung Antibodies | >10 publications with SIRPA and Lung |
| Bone Marrow Antibodies | >9 publications with SIRPA and Bone Marrow |
| Skin Antibodies | >9 publications with SIRPA and Skin |


